Table 2

BRAF mutant-specific genesa,b

Probe setDescriptionFold changecMean changedRank
40406_atMacrophage stimulating, pseudogene 95.7 (4.0–8.5)1011
32115_r_atAdenosine A2a receptor4.2 (1.6–7.5)1692
1047_s_atHuman hepatocyte growth factor-like protein gene3.6 (2.4–5.3)2463
40237_atTumor-suppressing subtransferable candidate 33.5 (1.7–5.9)1084
34094_i_atHuman immunoglobulin heavy chain variable region3.3 (2.3–5.9)5105
37473_atKeratin 163.1 (2.1–6.2)1796
34095_f_atHuman immunoglobulin heavy chain variable region2.8 (2.0–4.0)10417
35350_atB-cell RAG-associated protein2.3 (1.8–3.0)1628
40928_atSOCS box-containing WD protein SWiP-12.3 (1.5–3.2)7059
2017_s_atCyclin D12.2 (1.5–3.0)24310
38028_atNeuronal specific transcription factor DAT12.2 (1.8–2.8)16011
35566_f_atImmunoglobulin heavy constant mu2.1 (1.5–2.8)141912
31888_s_atTumor-suppressing subtransferable candidate 32.1 (1.5–2.7)32413
37323_r_atHydroxyprostaglandin dehydrogenase 15-(NAD)2.1 (1.3–2.9)18014
40317_atAmiloride-sensitive cation channel 12.0 (1.8–2.3)11715
32919_atHomo sapiens, clone IMAGE:36252862.0 (1.8–2.4)18416
  • a Comparison between 2 BRAF mutants and 57 WT (KRAS and BRAF).

  • b Genes were chosen by D-chip software (see “Materials and Methods”).

  • c Fold change (increase in BRAF mutants) with 90% lower and upper confidence bounds in parentheses.

  • d Difference between means of groups in normalized Affymetrix arbitrary expression values.